Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Co.don AG
  6. Summary
    CNWK   DE000A1K0227

CO.DON AG

(CNWK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Estimated financial data (e)
Sales 2021 9,80 M 11,5 M 11,5 M
Net income 2021 -12,7 M -14,8 M -14,8 M
Net cash position 2021 5,40 M 6,33 M 6,33 M
P/E ratio 2021 -3,91x
Yield 2021 -
Sales 2022 17,8 M 20,8 M 20,8 M
Net income 2022 -2,85 M -3,34 M -3,34 M
Net cash position 2022 0,10 M 0,12 M 0,12 M
P/E ratio 2022 -13,8x
Yield 2022 -
Capitalization 39,4 M 46,1 M 46,1 M
EV / Sales 2021 3,46x
EV / Sales 2022 2,21x
Nbr of Employees -
Free-Float 27,1%
More Financials
Company
Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is... 
Sector
Pharmaceuticals
Calendar
09/30 | 08:00am
More about the company
Ratings of co.don AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CO.DON AG
09/03CO.DON AG (ISIN : DE 000A3E5C08 / DE000A3E5C16) – Intended product out-licensing in ..
PU
09/03CO.DON Aktiengesellschaft Announces Intended Product Out-Licensing in the Asian Economi..
CI
08/26Co.Don Ag Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/17CO.DON AG : Start of routine production at the Leipzig site on time and on budget
PU
08/17CO.DON AG announces Start of Routine Production At the Leipzig Site on Time and on Budg..
CI
06/07CO.DON AG : GMP inspection of the higher federal authority and the Saxony state directorat..
PU
06/03CO.DON AG : Marketing authorisation granted for Spherox in the United Kingdom
PU
06/03Co.don Ag Announces Marketing Authorisation Granted for Spherox in the United Kingdom
CI
05/25CO DON : Secures European Regulator's Approval Extension for Spherox
MT
05/25CO.DON AG : EU-approved medicinal product receives vote for indication extension for use i..
PU
05/21CO.DON AG (ISIN : EN DE000A1K0227): EU-approved medicinal product receives vote for indica..
PU
05/21Co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of t..
CI
05/03Co.Don Ag Reports Earnings Results for the Full Year Ended December 31, 2020
CI
04/28CO.DON AG : Technology transfer process gets green light from EMA
PU
04/28Co.don AG Technology Transfer Process Gets Green Light from EMA
CI
More news
News in other languages on CO.DON AG
09/22CO.DON AG : CO.DON AG schließt Kapitalerhöhung ab
09/06CO.DON AG (ISIN : DE 000A3E5C08 / DE000A3E5C16) - co.don Aktiengesellschaft beschließt pro..
09/06CO.DON AG (VON SPHENE CAPITAL GMBH) : Buy
09/06CO.DON AG (VON SPHENE CAPITAL GMBH) : Buy
09/03CO.DON AG : CO.DON AG (ISIN: DE 000A3E5C08 / DE000A3E5C16) - Beabsichtigte Produktauslizen..
More news
Chart CO.DON AG
Duration : Period :
co.don AG Technical Analysis Chart | CNWK | DE000A1K0227 | MarketScreener
Technical analysis trends CO.DON AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,80 €
Average target price 8,40 €
Spread / Average Target 367%
EPS Revisions
Managers and Directors
Tilmann Bur Chief Executive Officer
Hans B. Bauerfeind Chairman-Supervisory Board
Thomas Stńhlin Vice Chairman-Supervisory Board
Barbara SickmŘller Member-Supervisory Board
Thomas Krause Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
CO.DON AG0.00%46
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336